

Workshop Japan-Egypt
“Pharmacognosy and Traditional Medicine”

July 20–23 2010, Tokyo, Japan




Maximizing Peptide and Protein Absorption via Noninvasive Route of Administration

Over the past several decades, biotechnology has developed extensively and led to a significant increase in the number of bioengineered products. Now, the market is growing rapidly and remarkably.


Ranking	Drug
4	Rituximab
5	Etanercept
6	Infliximab
9	Erythropoietin α
10	Bevacizumab
11	Trastuzumab
15	Adalimumab
25	Insulin Glargine
28	Darbepoetin α
29	Pegfilgrastim

2008 world drug market



Various strategies have been pursued over the past few decades to develop safe and effective noninvasive delivery systems for biodrugs. However, the success in the clinical application is limited.


Carrier Development for Biodrugs



M. Morishita et al., **JCR**, 2006

T. Goto et al., **Pharm Res**, 2006

How Can We Increase the BA of Biodrugs from Noninvasive Route of Administration ?



What is the most practical approach?

The key to make the delivery succeed is to maximize **Fa**

Modifying the physicochemical nature of macromolecules

(hydrophobicity↑、 stability to enzymes↑)

Fa ↑

Adding novel functionality to macromolecules

(use of endogenous cellular transport systems)

Fa ↑





Development of superior delivery carriers

Fa ↑ Fg ↑

Materials Delivered Inside Cells by CPPs

Particulate Carriers

Gold nanoparticles
(20nm)



Chemical
conjugation


Proteins and Nucleic acids

Beta-galactosidase
Horseradish peroxidase
Green fluorescent protein
Antibody
p53
Ribonuclease
siRNA

Chemical conjugation
Fusion protein
Physical mixture

Cell Penetrating Peptide (CPP)

(arginine rich cationic peptide)




enhancement of
internalization

Cell

Nucleus

M. Morishita and N.A. Peppas,
Drug Discovery Today, 2006

Can we use CPP Strategy for the noninvasive biodrug delivery systems ?



If so, which is more useful strategy, covalent or noncovalent?

The CPP Strategy by Chemical Conjugation

Leuprolide

pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHCH₂CH₃

Leuprolide-D-R6 conjugate

pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-Arg-Arg-Arg-Arg-Arg-Arg-D-Lys(FITC)-NH₂
D-form


In situ loop absorption study

Animal: Male Wistar rats (weight 180-220 g)

Segment: Ileum


Analysis: Plasma testosterone concentration
(Enzyme immunoassay method)

Replication: n=3 (mean ± S.D.)




Effectiveness of Covalent Strategy

Plasma testosterone concentration -
time profiles



In situ ileal loop absorption study in rats

N. Kamei et al., **JCR**, 2008





increase in MW

increase in hydrophilicity

decrease in pharmacological
activity (36%)

Effectiveness of Noncovalent Strategy

Plasma insulin
concentration -time profiles




Remarkable improvement of intestinal
peptide absorption was attained by
physical mixture of D-R6

Advantage of physical mixture:


- preservation of pharmacological activity
- retention of physicochemical characteristics
- ease of the preparation

Safety of Noncovalent Strategy



TEER Values of intestine



Histopathology of Intestinal Mucosa




Histopathology of Nasal Mucosa



Suggesting mucosal membrane integrity was maintained following the application of CPP

Molecular Imaging Analysis of Intestinal Insulin Absorption Boosted by CPP



⁶⁸Ga-labeling method



Intestinal absorption and subsequent distribution of insulin were quantitatively analyzed using molecular imaging technique based on positron emission tomography (PET).

Experimental method

In situ loop投与実験



理研分子イメージング科学研究センターHPより転載

動物: SD系雄性ラット (体重: 180-220g)

固定: 背位固定

薬物: インスリン (cold, 132 μM) に ⁶⁸Ga-DOTA-インスリン (約4 μM) を添加

CPP: L-R8, D-R8 and L-penetratin (1000 μM)

投与方法: 回腸ループ内に薬物-CPP混合溶液を投与


前処理: 大豆トリプシンインヒビター (10 mg/mL)

血液採取: 尾静脈採血


検出方法: PET (microPET® Focus 220, Siemens社製)

Molecular Imaging Analysis of Intestinal Insulin Absorption Boosted by CPP


liver ^{68}Ga -DOTA-insulin





Kidney ^{68}Ga -DOTA-insulin



Blood ^{68}Ga -DOTA-insulin



Blood glucose level




Time course of maximum intensity projection based on the PET imaging

^{68}Ga -DOTA-insulin after administration from the intestine was rapidly passed through the liver and significantly accumulated into the kidney. By co-administrating with D-R8 and L-penetratin, ^{68}Ga -DOTA-insulin levels in the liver, kidney and circulation was significantly increased, and the resultant hypoglycemic effect was observed.

➡ This is the first PET imaging study of intestinal insulin absorption in the presence of CPP.

What is the mechanism for improving biodrug absorption?



- universal vector ?-

Key is intermolecular interaction

Intermolecular Interaction


**Significant
improvement**

**Insulin
GLP1
Gastrin**

**Weak
improvement**

**Exendin-4
Interferon beta
Leuprolide
Calcitonin**

D-R8



Hypothesis

“Electrostatic interaction” between drug and CPP may be related to intestinal drug absorption enhancing effects.

Method for Binding Characteristics of Biodrug to D-R8

Surface plasmon resonance (SPR)



Apparatus: BIAcore 2000

Sensorchip: Streptavidin-immobilized chip
Carboxymethyl dextran chip

Immobilized ligand: Biotinylated D-R8, insulin

Analyte: D-R8, Gastrin, insulin, calcitonin, etc.

pH: 6.0



~Calculation of bound concentration~

$$\text{Analyte}_{\text{total}} = \text{Analyte}_{\text{free}} + \frac{B_{\text{max}} \cdot \text{Analyte}_{\text{free}}}{K_D + \text{Analyte}_{\text{free}}}$$

$$B_{\text{max}} = \text{Ligand}_{\text{total}} \times \text{Binding ratio (analyte/ligand)}$$

In situ loop absorption study

Animal: Male SD rats (weight 180-220 g)


Segment: Ileum

Drug: Insulin, gastrin, exendin-4, calcitonin (132 μM)

CPPs: D-R8 (50-2620 μM)

pH: 6.0

Replication: N=3-5 (mean \pm S.E., * $p < 0.05$ vs. control)




Binding Characteristics of Biodrug to D-R8

Characteristics of Biodrugs


	Mw	pI
Gastrin	2098	2.77
Exendin-4	4187	4.49
Oxytocin	1007	5.20
Insulin	5808	5.3
GLP-1	3298	5.46
Leucine Enkephalin	556	5.68
TRH	362	7.85
Angiotensin	1296	7.96
[Arg ⁸]-Vasopressin	1084	8.28
Calcitonin	3492	9.03
Somatostatin	1638	9.16
Leuprolide	1209	9.65
LH-RH	1182	9.65
Mastoparan	1479	10.85
ACTH	2933	11.05
Dynorphin A	2147	11.45

Gastrin




Bound gastrin
59.4%

Insulin




Bound insulin
58.7%

Exendin-4




Calcitonin






No interaction
was observed

Effect of D-R8 on the Ileal Absorption of Biodrugs

Gastrin





Insulin





Effect of D-R8 on the Ileal Absorption of Biodrugs

Exendin-4




Calcitonin





➡ Suggesting that intermolecular binding between drug and CPP is an important factor governing the enhancing effect of the CPP on their intestinal absorption.

What kind of CPP is safe and useful?





Effect of Different CPP on the Ileal Insulin Absorption

CPP	Amino acid sequence
Penetratin	RQIKIWFQNRRMKWKK
pVEC	LLILRRRIRKQAHASK
RRL helix	RRLRLLRRLRLLRRLR
Rn	Rn (n=6, 8, 10)
HIV-I Tat	GRKKRRQRRPPQ
HIV-I Rev	TRQARRNRRRRWRERQR



M. Morishita et al., J Control. Release, 2007

Perspectives




El-Sayed Khafagy et al., JCR, 2009

Conclusions and Perspectives

- Is the CPP useful as a promoting tool of noninvasive biodrug absorption?

YES



Several CPPs significantly enhanced intestinal and nasal absorption of biodrugs. The most significant enhancement effect was observed with penetratin analogs.

The absorption enhancement effects were demonstrated by physical mixture and does not need chemical conjugation. In addition, the enhancement was not associated with cellular damage and diffusion.

Therefore, CPP are likely to become powerful tools for overcoming the low permeability of biodrugs through the epithelial cell membranes: the major barrier to macromolecular drug delivery.

Collaborators



Prof. Takayama and lab members




Dr. Watanabe

Riken Kobe Institute
Center for molecular imaging sciences



Dr. Nakanishi

the National Institute of
Advanced Industrial Science
and Technology



Dr. Kamei



Dr. El.-S. Khafagy



Mr. Terasawa

Mr. Yamamoto

東レ株式会社 先端融合研究所
カプセル・ジャパン（ファイザーグループ）
持田製薬株式会社、 日本水産株式会社